The radioimmunoassay market is a critical diagnostic tool that offers accurate and sensitive detection of various substances in blood, urine, and tissues including hormones, vitamins, drugs, and tumor markers.

The global radioimmunoassay market size is estimated to be valued at US$ 518.85 Mn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period from 2024 to 2031.

Radioimmunoassay is an analytical technique which measures minute quantities of biological substances like hormones, vitamins, and drugs. It has applications in various disease detection including cancer, heart disease, and diabetes. The use of radioisotopes as labels makes the assay highly sensitive and accurate for quantitative measurements. Factors such as rising chronic disease prevalence, improving access to healthcare facilities, and increasing healthcare expenditure are augmenting the demand for Radioimmunoassay Market Share globally. The Global Radioimmunoassay Market is estimated to be valued at US$ 518.85 Mn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in the radioimmunoassay market are Schneider Electric SE, Accuvio Sustainability Software, Cority Software Inc., IBM Corporation, Johnson Controls, Dakota Software Corp, Accenture PLC, Enablon SA and SAP SE. These players are focusing on new product launches and collaborations to consolidate their market share.

The growing prevalence of lifestyle diseases and various cancers is driving the demand for radioimmunoassays as these tests are commonly used for monitoring the disease progression and treatment efficacy. According to the World Health Organization, cancer is the second leading cause of death globally and was responsible for nearly 10 million deaths in 2020.

Technological advancements are enabling miniaturization and automation of radioimmunoassay instruments. Developments such as microfluidic biosensors, high-throughput assays, and lab-on-a-chip technology are simplifying testing procedures and reducing turnaround times. This is facilitating the integration of radioimmunoassay offerings in point-of-care settings.

Geographic Concentration of Market
Europe closely follows North America as the second largest regional market for radioimmunoassay. Presence of prominent players, large patient pool, favorable reimbursement policies, and widespread acceptance of radioimmunoassay in clinical research and disease screening are augmenting the European market. Within Europe, radioimmunoassay market witnesses maximum value concentration in countries like Germany, UK, France, Italy and Spain owing to well-developed healthcare systems and growing geriatric population susceptible to chronic conditions.

Get more insights on Radioimmunoassay Market